MANY STUDIES HAVE led to the concept that membrane phospholipid asymmetry is ubiquitous. In general terms, the outer leaflet of eukaryotic plasma membranes is formed predominantly with the cholinephospholipids (sphingomyelin and phosphatidylcholine [PC]), whereas the majority of the aminophospholipids (phosphatidylserine [PS] and phosphatidylethanolamine [PE]) are confined to the membrane's inner leaflet. This selective localization dictates that asymmetric biomembranes are assembled and maintained by specific mechanisms that control transbilayer lipid sidedness. In 1984, it became clear that asymmetry was generated by the activity of an adenosine triphosphate (ATP)-dependent aminophospholipid translocase that specifically transports PS and PE between bilayer leaflets.1 This discovery underscored the prevailing concept that membrane lipid asymmetry was of major physiologic importance, because it showed that cells invest energy to catalyze lipid movement in order to maintain a specific transmembrane phospholipid distribution.

Although asymmetry is the rule for normal cells, loss of asymmetry, especially the appearance of PS at the cell surface, is associated with many physiologic and pathologic phenomena. Bevers et al2,3 were the first to report that the asymmetric orientation of phospholipids in blood platelets was rapidly lost upon influx of calcium during their activation, a finding that suggested a critical role for PS in thrombosis.4,5 Apoptotic6-9 and tumorigenic cells10,11 also express relatively large amounts of outer-leaflet PS that may serve as a trigger for macrophage recognition and promote the cells' phagocytosis.12-15 

In this essay, we summarize recent observations on the perturbation of membrane phospholipid asymmetry and present a somewhat stochastic view of the patho-physiologic implications of surface-exposed PS. We also review briefly the mechanisms believed to be responsible for the regulation of phospholipid distributions across plasma membranes. Other details of transbilayer lipid distributions and the various techniques used in this field will not be discussed; several recent reviews of these and related topics have been published elsewhere.16-21 

At least three distinct activities are involved in the regulation of membrane lipid sidedness. Two energy-requiring activities seem to work in concert to maintain a nonrandom transbilayer phospholipid orientation. Inhibition of these activities stops lipid movement, but it does not result in loss of asymmetry for at least several days in vitro. Influx of Ca2+ into the cytoplasm, on the other hand, activates a scramblase activity that results in rapid transbilayer phospholipid mixing that leads to a nearly symmetric distribution of phospholipids across the membrane bilayer (Fig 1).

Fig. 1.

The regulation and physiology of membrane phospholipid asymmetry. This model describes how membrane phospholipid asymmetry is generated, maintained, and perturbed as a prerequisite to various phosphatidylserine-related pathophysiologies. Membrane lipid asymmetry is regulated by the cooperative activities of three transporters. The ATP-dependent aminophospholipid-specific translocase, which rapidly transports PS and PE from the cell's outer-to-inner leaflet; the ATP-dependent nonspecific lipid floppase, which slowly transports lipids from the cell's inner-to-outer leaflet; and the Ca2+-dependent nonspecific lipid scramblase, which allows lipids to move randomly between both leaflets. The model predicts that the translocases are targets for Ca2+ that directly regulates the transporter's activities. The figure shows that elevated intracellular Ca2+ induces PS randomization across the cell's plasma membrane by providing a stimulus that positively and negatively regulates scramblase and translocase activities, respectively. At physiologic Ca2+ concentrations, PS asymmetry is promoted because of an active translocase and floppase but inactive scramblase. Depending on the type of cell, elevated intracellular Ca2+ levels can be achieved by cellular activation that generally results in the concomitant influx and accumulation of extracellular Ca2+ and by its release from intracellular stores. Increased cytosolic Ca2+ can also result in calpain activation, which facilitates membrane blebbing and the release of PS-expressing procoagulant microvesicles. Exposure of PS at the cell's outer leaflet. The appearance of PS at the cell's outer leaflet promotes coagulation and thrombosis by providing a catalytic surface for the assembly of the prothrombinase and tenase (not shown) complexes and marks the cell as a pathologic target for elimination by phagocytes. Recognition of the PS-expressing targets can occur by both antibody-dependent and direct receptor-mediated pathways. (Aminophospholipids are shown with red polar headgroups and cholinephospholipids with blue polar headgroups, see cover photo; β2-Gp, β2-glycoprotein-I; rec, receptor).

Fig. 1.

The regulation and physiology of membrane phospholipid asymmetry. This model describes how membrane phospholipid asymmetry is generated, maintained, and perturbed as a prerequisite to various phosphatidylserine-related pathophysiologies. Membrane lipid asymmetry is regulated by the cooperative activities of three transporters. The ATP-dependent aminophospholipid-specific translocase, which rapidly transports PS and PE from the cell's outer-to-inner leaflet; the ATP-dependent nonspecific lipid floppase, which slowly transports lipids from the cell's inner-to-outer leaflet; and the Ca2+-dependent nonspecific lipid scramblase, which allows lipids to move randomly between both leaflets. The model predicts that the translocases are targets for Ca2+ that directly regulates the transporter's activities. The figure shows that elevated intracellular Ca2+ induces PS randomization across the cell's plasma membrane by providing a stimulus that positively and negatively regulates scramblase and translocase activities, respectively. At physiologic Ca2+ concentrations, PS asymmetry is promoted because of an active translocase and floppase but inactive scramblase. Depending on the type of cell, elevated intracellular Ca2+ levels can be achieved by cellular activation that generally results in the concomitant influx and accumulation of extracellular Ca2+ and by its release from intracellular stores. Increased cytosolic Ca2+ can also result in calpain activation, which facilitates membrane blebbing and the release of PS-expressing procoagulant microvesicles. Exposure of PS at the cell's outer leaflet. The appearance of PS at the cell's outer leaflet promotes coagulation and thrombosis by providing a catalytic surface for the assembly of the prothrombinase and tenase (not shown) complexes and marks the cell as a pathologic target for elimination by phagocytes. Recognition of the PS-expressing targets can occur by both antibody-dependent and direct receptor-mediated pathways. (Aminophospholipids are shown with red polar headgroups and cholinephospholipids with blue polar headgroups, see cover photo; β2-Gp, β2-glycoprotein-I; rec, receptor).

Close modal

Aminophospholipid translocase.The discovery of an ATP-dependent aminophospholipid translocase in red blood cells has provided direct evidence for the existence of mechanisms that generate and maintain membrane asymmetry through the transport of specific lipids across the cell's membrane.1,22,23 This activity is distinguished by its ability to transport PS and PE from the outer to inner leaflet of plasma membranes against the concentration gradient. Cholinephospholipids are not moved. Competition experiments have shown that the same protein transports both PS and PE, although PS is transported much faster, with half-times of 5 to 10 minutes.24,25 This process consumes one molecule of ATP per molecule of lipid transported.26 Transport is stereospecific for naturally occurring L-isomers of the glycero-backbone27 and is inhibited by vanadate,1 sulfhydryl-reactive reagents,28,29 and the histidine-reactive reagent bromophenacylbromide.25 In addition, activity is abrogated when cytoplasmic Ca2+ levels reach micromolar concentrations.30 31 

Although these observations clearly indicate that lipid transport is catalyzed by one or more membrane proteins, its identity is still uncertain. A 110-kD Mg2+-ATPase has been partially purified32-34 and reconstituted into artificial lipid vesicles with at least a fraction of its active center at the outer face.35 These vesicles transported a spin-labeled PS analog from the inner to outer leaflet upon the addition of Mg2+-ATP, suggesting that this ATPase is responsible for aminophospholipid translocation. However, it was recently reported that, similar to previous purification strategies,33 the active fraction was not homogenous and contained several proteins ranging from 35 kD to 120 kD.36 These observations preclude assignment of the transporter to a single protein and are not inconsistent with studies implicating the involvement of a 30-kD to 32-kD band 7 transmembrane polypeptide in aminophospholipid transport.28,37,38 This protein, which may be complexed to Rh polypeptides, was preferentially labeled in erythrocyte membranes with a photoactivatable PS analog only under conditions conducive to PS transport.25,39,40 Consistent with these observations, aminophospholipid transport activity was suggested to require the coordinated and complimentary participation of a Mg2+-ATPase and a 32-kD protein,16 a motif not uncommon for the ATP-binding cassette (ABC) family of proteins to which the aminophospholipid translocase might belong.41 42 

Aminophospholipid translocase activity has been observed in other membranes, including intracellular chromaffin granule membranes43 and endoplasmatic reticulum.44 Activity has also been shown in various cells,31,45-50 including endothelial cells, in which its expression is regulated by basic fibroblast growth factor.51 Mutants defective in PS transport have been isolated.52 

ATP-dependent floppase.Another ATP-dependent translocating activity has been described that, in conjunction with the aminophospholipid translocase, may regulate the differential transbilayer orientation of phospholipids in complex biologic membranes. A less specific ATP-requiring floppase, first discovered in red blood cells, transports both aminophospholipids and cholinephospholipids from the inner to the outer leaflet with half-times about 10 times longer than those of the translocase-mediated inward movement of PS and PE.25,53-55 Similar to inward transport of aminophospholipids, outward movement was found to be abrogated by ATP depletion, sulfhydryl oxidation, and histidine modification, indicating that this process is also energy- and protein-dependent.25 Whether outward transport is an intrinsic property of the aminophospholipid translocase or is caused by the activity of a distinct membrane protein or protein complex is not known. Because rapid inward translocation of aminophospholipids does not accelerate outward migration of all phospholipids, both processes may be mediated by independent mechanisms.25 Nonetheless, both lipid-transporting activities seem to act in concert and establish a dynamic asymmetric steady-state in which all phospholipids are slowly but continuously moved to the outer membrane surface, whereas the aminophospholipids are shuttled directly back to the inner leaflet.21,25 Thus, the combined action of translocase and floppase seems to equip the cell with a mechanism that corrects for alterations in lipid distributions to avoid potential pathologic consequences. Whereas the maintenance of membrane lipid is asymmetry is stable and resistant to the mechanical stresses56 likely endured in the peripheral circulation, rapid perturbations in lipid asymmetry could be coincident to different membrane fusion events that accompany endocytosis and exocytosis.17,31 57-60 

Lipid scramblase.Platelet plasma membranes harbor a Ca2+-dependent mechanism that can rapidly move phospholipids back and forth between the two membrane leaflets (flip-flop), leading within minutes to a loss of membrane lipid asymmetry.2,3 Because the influx of Ca2+ also abrogates aminophospholipid translocase activity,30,31,46 Ca2+-dependent loss of membrane phospholipid asymmetry is not corrected. Considering that spontaneous transbilayer migration of lipids is thermodynamically unfavorable, Ca2+-induced lipid randomization is likely to depend on a protein or proteins with lipid scramblase activity.61 Indeed, the existence of an inherited bleeding disorder (Scott syndrome, see below), characterized by an impairment of scramblase activity, reinforces the notion that specific membrane proteins are involved in this process.62-64 Ca2+-induced scramblase activity has also been found in other cells, but its activity is usually lower than in blood platelets (reviewed previously16 18 ).

Scramblase activity requires the continuous presence of cytoplasmic calcium.65 Provided the aminophospholipid translocase is not irreversibly inactivated by intracellular calpain, Ca2+ efflux can lead to restoration of lipid asymmetry.57 Lipid scrambling is bidirectional, and all major lipid classes move back and forth at comparable rates.46,65,66 Unlike the energy-dependent translocase and floppase, the lipid scramblase does not require hydrolyzable ATP. However, its activity partially decreases during prolonged ATP depletion.67,68 Proteins fractionated from platelet membranes have been reconstituted into artificial lipid vesicles, which exhibited Ca2+-dependent lipid-scrambling activity that was pronase-, heat-, and sulfhydryl-sensitive.69 Similar experiments performed with proteins from red blood cell membranes suggested that a 37-kD protein may be responsible for lipid scrambling activity.70 Although these data indicate that a protein is responsible for scramblase activity, it has also been proposed that lipid scrambling is the result of a complex between phosphatidylinositol 4,5-bisphosphate and calcium.67 In addition to the protein reconstitution studies, other experiments also indicate that such a mechanism cannot account for the scramblase activity observed in platelets.71 

Loss of membrane lipid asymmetry is often accompanied by blebbing and subsequent shedding of lipid-symmetric microvesicles from the cell surface.57,72-75 Fusion between opposing segments of plasma membrane before the release of microvesicles was proposed to cause a localized collapse of lipid asymmetry.72 However, recent evidence indicates that this is not the mechanism responsible for lipid scrambling because (1) Ca2+-induced randomization of lipids can occur in the absence of microvesicle formation under conditions in which activation of intracellular calpain is prevented75-77 and (2) lipid scrambling and microvesicle formation are deficient in Scott syndrome72 but calpain activity is normal.62 Thus, at least both lipid scrambling and calpain activation are required for shedding of microvesicles (Fig 1).

In summary, the synchronous and cooperative action of the aminophospholipid translocase and the nonspecific floppase contribute to the generation and maintenance of membrane phospholipid asymmetry, whereas lipid scramblase activity results in its collapse. At physiologic (ie, low) cytoplasmic Ca2+ levels, both aminophospholipid translocase and nonspecific floppase are active, and phospholipid asymmetry is maintained. Conversely, high cytoplasmic Ca2+ concentrations activate lipid scramblase and block the cooperative action of translocase and floppase, leading to randomization of phospholipids across the membrane lipid bilayer. Conceivably, intermediate Ca2+ levels could lead to a circumstance in which both mechanisms are active and oppose each other.21 These situations can accommodate a wide range of steady-state distributions of membrane phospholipids commonly seen in in vitro stored red blood cells,78-80 sickle cells,81-84 blood cells from diabetics,85,86 aged red blood cells,87,88 and undifferentiated tumorigenic cells.10 11 

Other mechanisms.Many studies have suggested that cytoskeletal proteins assist in the maintenance of membrane phospholipid asymmetry by selectively interacting with aminophospholipids.89-91 However, the interaction between PS and cytoskeletal proteins is thermodynamically weak and there is evidence that lipid asymmetry can be generated and maintained in artificial membrane preparations that lack cytoskeletal proteins.26,92,93 Moreover, spherocytic erythrocytes fully conserve lipid asymmetry despite markedly diminished levels of spectrin.94 Although these observations do not unequivocally rule out the cytoskeleton's function in the maintenance of lipid asymmetry, it is presumably not of major importance.

Another group of proteins that translocate lipid or lipid-soluble compounds across the plasma membrane have recently received wide attention. Unidirectional transport of PC is catalyzed by a member of the P-glycoprotein family in the canalicular domain of murine hepatocyte plasma membranes to provide PC for bile production.95,96 This membrane glycoprotein is encoded by the murine multidrug resistance gene mdr2 and belongs to the family of ABC proteins. Although its behavior resembles that of the ATP-dependent translocase and floppase, its lipid specificity is clearly different. Moreover, its presence may be restricted to hepatocyte membranes, precluding a role in establishing lipid asymmetry in other cells. However, P-glycoprotein encoded by the mdr1 gene is abundantly expressed in drug-resistant tumor cells, where it nonselectively expels lipid-soluble compounds from the inner to the outer membrane leaflet.97 98 Although the properties of the mdr1 P-glycoprotein resemble those of the nonselective red blood cell floppase, their possible relationship remains to be explored.

A recent proposal is that, unlike phospholipid scrambling in red blood cells, PS exposure in activated platelets is caused by a vectorial inward-outward aminophospholipid-specific transport mechanism.99,100 This conclusion contrasts with observations from other laboratories that show Ca2+-induced lipid scrambling involves nonspecific flip-flop of all lipid classes.3,46,65,66,72,101 Platelets are unlikely to have a specific mechanism different from that of red blood cells because the hereditary abnormality in PS exposure in Scott syndrome equally affects both platelets and erythrocytes.102 Moreover, insurmountable shape changes would be produced by the large mass-imbalance generated when outward transport of aminophospholipids is not compensated by inward transport of other lipids.18 Indeed, less than 1% of a mass imbalance produces large shape changes in giant unilamellar liposomes.103 Although the cell might be able to compensate for bilayer imbalances by releasing microvesicles, PS exposure in platelets can occur without microvesicle release.77 

Lipids and coagulation.Membrane phospholipids propagate the proteolytic reactions that result in thrombin formation by promoting the assembly of coagulation factors on their surface. The most important pathway of coagulation is initiated by tissue factor, an integral membrane protein expressed on the surface of activated or disrupted cells.104-107 Tissue factor interacts with factor VII or VIIa, and this complex rapidly converts the zymogen factor IX, factor X, and factor VII itself into their active forms. Although assembly and catalytic activity of the tissue factor/factor VIIa complex is effective in the absence of anionic phospholipids, activity is increased by PS.108-110 However, anionic phospholipids are indispensable in promoting membrane binding and catalytic activity of the two subsequent coagulation factor complexes in the cascade that leads to thrombin formation.106,111 The tenase complex is initiated by the interaction of factor VIIIa with negatively charged lipid to create a high-affinity binding site for the enzyme factor IXa in the presence of Ca2+. This complex rapidly activates factor X into Xa. Likewise, in the prothrombinase complex, binding of factor Va to an anionic lipid surface promotes Ca2+-dependent binding of factor Xa, which converts prothrombin to thrombin (Fig 1). In both complexes, PS is the most effective anionic phospholipid.112 Binding of factors Va and VIIIa to naturally occurring phosphatidyl-L-serine is stereospecific and occurs with lower affinity to phosphatidyl-D-serine and other anionic phospholipids.113,114 PS is equally important in promoting the anticoagulant protein C pathway that provides feedback inhibition of thrombin formation. Protein C effectively inactivates factor Va when both are bound to the same lipid surface, which leads to disassembly of the prothrombinase complex.105 115 

Procoagulant activity of blood platelets.Surface exposure of PS in platelet membranes provides for efficient propagation and control of the hemostatic process. Kalafatis et al106 have argued that specific protein receptors for factors Va and VIIIa may, in addition to PS binding sites, be present in cellular membranes. However, it should be noted that phospholipases116 and annexin V117 inhibit platelet prothrombinase activity. Although this does not eliminate the putative existence of protein receptors, these data prove that PS exposure is critical to coagulation. However, because platelets do not contain tissue factor they cannot initiate the coagulation cascade. Moreover, annexin V inhibits prothrombin activation only in cells that express both tissue factor- and prothrombinase-binding sites.118 These data indicate that surface exposure of PS is required for propagation but not necessarily for initiation of the coagulation process.

The extent to which membrane phospholipid asymmetry becomes perturbed during platelet activation correlates with the cells' ability to promote tenase and prothrombinase activity119 and depends on the type of agonist.3,72,120,121 Ca2+-ionophore is the most effective followed by complement membrane attack complex C5b-9, collagen + thrombin, collagen, and thrombin. ADP and epinephrine have no effect. The same order of agonist activity is observed for the extent of lipid-symmetric microvesicle shedding from the platelet surface.72 75 

Platelet activation after vascular damage involves adhesion to subendothelial structures and aggregation of platelets to form a primary hemostatic plug at the wound site. The exposure of PS on aggregated platelets restricts and controls thrombin formation at the site of injury by providing a catalytic membrane surface for both procoagulant (tenase and prothrombinase) and anticoagulant (protein C) reactions. The physiologic significance of platelet-derived microvesicles is not clear. Because microvesicles tend to circulate rather than stick to the platelet aggregate, it is thought that they may be associated with thrombotic conditions. Indeed, increased amounts of circulating microvesicles have been observed in patients suffering from various disorders associated with secondary activated coagulation122 and in patients with such primary thrombotic disorders as transient ischemic attacks and myocardial infarction.123,124 It has also been shown that platelet microvesicles bind to and activate neutrophils, suggesting that hemostasis and inflammation may be linked.125 Indeed, it has recently been shown that the leukocyte adhesion molecule L-selectin binds PS.126 Thus, activation and aggregation of platelets at the site of injury could recruit leukocytes to the site of inflammation via the binding of platelet-exposed PS to leukocyte L-selectin. Unlike platelet-derived microvesicles, microparticles released from other cells may also contain tissue factor activity and initiate undesired coagulation in the circulation.118,127 128 

Scott syndrome, a disorder of Ca-induced lipid scrambling.Scott syndrome, which was first described by Weiss et al,129 is a rare, moderately severe, bleeding disorder characterized by a deficiency in platelet procoagulant activity that is not associated with decreased coagulation factor levels.63 Although activation of these platelets results in normal secretion and aggregation, they express a relatively low number of factor Va and VIIIa binding sites.130,131 These cells exhibit decreased surface exposure of PS, reduced ability to promote both tenase and prothombinase activity in response to agonists,62 and impaired capacity to shed membrane-derived microvesicles.72 Studies of a recently discovered family in France indicated that Scott syndrome is an inherited bleeding disorder transmitted as an autosomal recessive trait.64 Remarkably, the defect in Ca2+-induced lipid scrambling is not restricted to platelets but can also be shown in the patients' erythrocytes, erythrocyte ghosts,102 and in Epstein-Barr virus-transformed B-lymphocytes.64,132 Experiments with single-cell clones of transformed lymphocytes have suggested that the reduced exposure of PS affects all cells to the same extent. Fusion of the lymphoblasts with a myeloma cell line restored PS exposures to normal levels.132 Platelets and erythrocytes from patients with Scott syndrome have normal phospholipid composition and show no obvious protein abnormality when examined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.102 Taken together, these studies support the notion that Scott syndrome results from a deletion or mutation in multiple hematologic lineages that either affects the putative phospholipid scramblase directly or alters the Ca2+-induced activation mechanism.

Procoagulant activity of red blood cells.Although red blood cells lose phospholipid asymmetry and stimulate prothrombinase activity after the addition of Ca2+-ionophore,54,57,66,68,133 they are not considered significant in hemostasis and thrombosis. However, the possibility that perturbations in PS exposure contribute to thrombotic events commonly seen in diabetes mellitus and sickle cell crisis should not be dismissed. Indeed, increased procoagulant activity associated with loss of lipid asymmetry has been observed in erythrocytes incubated in hyperglycemic buffers,86 in platelets from diabetic patients,134 and in vesicles shed from reversibly sickled cells by repeated hypoxia-induced sickling.91 Interestingly, Ca2+-induced transbilayer movement of PS and the generation of red blood cell procoagulant activity is strongly inhibited by high-density lipoprotein (HDL) and apolipoprotein A-1135; this raises the possibility that the protective effect of HDL against arterial thrombosis may be due, in part, to HDL-dependent inhibition of thrombogenic surface expression.

Procoagulant activity of white blood cells.Although lipid sidedness has not been investigated in white blood cells, functional assembly of the prothrombinase complex on monocytes, neutrophils, and lymphocytes has been found to be kinetically equivalent to artificial PS-PC vesicles.136,137 The prothrombinase activity of monocytes is enhanced by endotoxin activation, a result that supports the notion that their ability to contribute to thrombin formation is important in the thrombotic events associated with inflammation and healing.138,139 Interestingly, the prothrombinase activity of activated monocytes can be enhanced by a reduction in their ATP levels and reduced by inhibition of protein synthesis. These observation may be directly related to the appearance of PS at the cell surface. Hypothetically, reduction of ATP would result in inhibiting the aminophospholipid translocase and prevent recovery from the cell's procoagulant state. Conversely, inhibition of protein synthesis would limit expression of the lipid scramblase and prevent PS exposure. Because stimulated monocytes also release microvesicles that express tissue factor activity,138-141 they have the capacity both to initiate and propagate coagulation in response to an inflammatory stimulus.

Complement activation of endothelial cells.Consistent with the principal anticoagulant function of endothelial cells, prothombinase assembly, even when stimulated with Ca2+-ionophore, is poorly supported on these cells.142 However, an interesting exception is observed upon insertion of complement membrane attack complex C5b-9. In this case, the assembled complement pore is removed from the cell by shedding into procoagulant microvesicles. The remnant cell, having discarded most of the complex, remains mainly noncoagulant.142 A similar mechanism of complement-mediated formation of procoagulant microvesicles occurs in platelets.121 This raises the possibility that complement-induced release of microvesicles into the circulation could contribute to inflammation-associated disseminated intravascular coagulation.

Complement-induced loss of lipid asymmetry in cell-derived microvesicles may be an intrinsic property of complement pore formation because incubation of lipid vesicles with C5b-9 causes transbilayer lipid exchange between both leaflets.143 Such pore-forming peptides as mellitin have also been shown to promote fast flip-flop of lipids in liposomes.144 These findings raise the possibility that the mechanism of Ca2+-induced phospholipid scrambling in plasma membranes requires the assembly of pore-forming membrane proteins. This model (Fig 1) envisions pore-mediated flip-flop of phospholipids to involve movement of polar headgroups through a central aqueous channel while the fatty acid moieties diffuse along a hydrophobic interface between subunits.144 145 Such a bidirectional transport mechanism implies that the size of the lipid headgroup, rather than its chemical composition, determines which molecules take part in this process and accounts for its lack of specificity.

Neoplasia and thrombosis.Laboratory evidence of hypercoagulability found in cancer patients is likely to be responsible for the symptomatic thromboembolic episodes frequently observed in these patients. The principal problematic features of blast cells are increased expression of tissue factor activity146-148 and the presence of a tumor-specific cysteine protease149-151 that directly activates factor X independent of the tissue factor pathway. In addition, different tumorigenic cells also express a catalytic surface that promotes the assembly and catalysis of the prothrombinase complex.10,11,118,152 Unlike tissue factor activity, the prothrombinase activity of tumorigenic cells is inhibited by annexin V118,153 because of competition for PS expressed at the cell surface. Tumor cells also release microvesicles that catalyze prothrombinase activity,152,154 a process similar to phospholipid scrambling and microvesicle release in other cells. The expression of both tissue factor and PS in the tumor cells and in their shed microvesicles128 could facilitate platelet-independent initiation and propagation of coagulation, and it may be responsible for fibrin deposits often seen in solid tumors.

Antiphospholipid syndome and thrombosis.Autoantibodies to phospholipid-binding proteins, which include lupus anticoagulants, comprise a heterogeneous group of circulating Igs that are associated with increased risk of arterial and venous thrombosis, thrombocytopenia, and recurrent abortions.155,156 Although these antibodies were first believed to recognize anionic phospholipids directly, recent evidence indicates that the antibodies are directed against various plasma proteins, particularly when these proteins are bound to anionic phospholipid surfaces.157-162 These include antibodies to lipid-bound β2-glycoprotein-I, prothrombin, protein C, and protein S. Interaction occurs whether the protein antigens are bound to model membranes, activated platelets, or platelet-derived microvesicles.163 Some patients have antibodies against only one of the phospholipid-binding proteins, whereas others display a variety of antigenic specificities. The relationship of these antibodies to thrombosis is not clear, especially when one considers that many antibody-positive individuals are asymptomatic. Whereas the presence of antibodies to β2-glycoprotein-I seems to be frequently associated with thrombosis, this relationship is less evident for antibodies against prothrombin, protein C, and protein S.162 This is rather unexpected considering the high thrombotic tendency of patients with hereditary protein C deficiency.

The mechanisms that elicit production of antibodies to lipid-bound serum proteins is unclear. Rather than an aberrant autoimmune response, the production of these antibodies may be a normal response against an antigenic epitope formed by interaction of the plasma proteins with a PS-expressing thrombogenic surface.9,159 Whatever the mechanism, antibodies against lipid-bound β2-glycoprotein-I or prothrombin usually prolong clotting times in vitro by preventing the assembly of prothrombinase or by inhibiting the proteolysis of prothrombin.157-159,161 It should be stressed that such a response does not necessarily lead to a bleeding tendency but may only reduce the propensity for thrombosis. Indeed, whereas thrombotic events are frequently observed in cancer, cancer patients who have lupus anticoagulant antibodies have been reported not to suffer from thromboembolic complications.164 

Recognition of PS by macrophages.Another feature of PS-expressing cells is their propensity to be recognized by the reticuloendothelial system.165,166 This was first shown by insertion of controlled amounts of fluorescent PS analogs into mouse red blood cells. Reinjection of these cells into syngeneic animals resulted in their rapid removal from the peripheral circulation and accumulation in splenic macrophages and Kupffer cells.13 Cell clearance depended on the amount of exogenously-inserted PS, and it occurred when the cells contained only about ∼1 mol% of the PS analog. However, clearance was incomplete. This was likely the result of aminophospholipid translocase activity, which continuously pumped PS to the inner leaflet of the circulating cells, thereby eliminating the putative PS ligand and preventing its recognition by macrophages. Anionic lipid-dependent binding to macrophages has also been observed with PS-containing liposomes in vivo167 and in vitro.168 169 These results underscore the potential significance of PS in cell-cell recognition and have led to the notion that specific receptor ligand interactions mediate the elimination of PS-expressing cells.

Recognition of PS-expressing cells.Normal cells do not expose significant amounts of PS, but pathologic cells seem to have undergone lipid rearrangements that result in PS exposure. Reorientation of PS has been observed, for example, in sickle cell disease79,81,83,84,91,120,170 and β-thalassemia,171 possibly because of decreased aminophospholipid translocase activity172 and alterations in passive diffusion rates of lipids between membrane leaflets,173 respectively. Apart from the thrombogenic state associated with these diseases, PS exposure might also explain the cells' increased susceptibility to phagocytosis. Indeed, macrophages bind PS-expressing deoxygenated sickle cells174 and leukemic cells10 by a mechanism that is PS-dependent. Recovery to a normal, non–PS-expressing, phenotype by reoxygenation of sickle cells174 or chemically induced differentiation of leukemic cells results in the disappearance of cell surface PS and reduction in macrophage binding.10 175 

Normal red blood cells seem to have an intrinsic property whereby they accumulate small amounts of surface-exposed PS over their lifespan.79,87,88 Given that macrophages are able to recognize PS, exposure of this lipid in aging red blood cells presumably contributes to their removal from the circulation. In vitro stored red blood cells also suffer from the gradual appearance of PS at the outer surface in an amount proportional to the duration of storage.79 Because aging cells progressively lose ATP-dependent enzymatic activities,176,177 both Mg2+-ATP–dependent aminophospholipid translocase and the Ca2+ pump will be affected. Conceivably, this condition leads to increased cytoplasmic Ca2+ levels that stimulate lipid scramblase and suppress aminophospholipid translocase. Indeed, aminophospholipid transport activity decreases upon storage of red blood cells78,178 and platelets.179 Because oxidation affects the activity of membrane lipid transporters,28,178,180-182 age-related alterations in the cells' redox state183 may also contribute to PS exposure and cell recognition.

PS expression during apoptosis.Apoptosis, defined by characteristic morphologic alterations and DNA fragmentation, is also accompanied by exposure of PS at the cell's outer surface. This was first shown by the ability of apoptotic lymphocytes to shorten clotting times in the PS-dependent Russell viper venom coagulation assay and by labeling of surface exposed PS with fluorescamine.6 The observation was later confirmed by direct measurement of annexin V binding to different apoptotic cells.7,8,184 Recent studies have shown convincingly that PS exposure is one of the earliest manifestations of apoptosis, and that it precedes DNA fragmentation, plasma membrane blebbing, and loss of membrane integrity.7 The process has been shown to be Ca2+-dependent and to involve bidirectional, nonspecific flip-flop of phospholipids.185 Although a PS-specific reverse translocase has been suggested to be responsible for this process,7 there is no evidence that such a transporter exists. Because the appearance of PS in apoptosis shares features typical of the collapse of membrane phospholipid asymmetry in activated platelets, it is most likely that apoptotic cell membrane lipid asymmetry is compromised by the combined actions of an activated scramblase and inhibited translocase.21 Conceivably, these events could be accompanied by membrane unpacking, which has also been shown to precede DNA fragmentation.186,187 This proposed mechanism is also consistent with the observation that calpain inhibitors prevent the characteristic blebbing and microvesiculation common to both platelet activation72 and apoptosis.188 

PS receptors in macrophages.The mechanisms of PS-mediated cellular recognition by macrophages probably involve several distinct pathways (Fig 1). Inflammatory macrophages can recognize PS-expressing apoptotic lymphocytes via a specific PS receptor that is inhibited by liposomes containing phosphatidyl-L-serine but not by other anionic phospholipids, including phosphatidyl-D-serine.6 Whether this receptor is the same as macrosialin (CD68),189 the 94- to 97-kD membrane protein that binds PS-expressing cells and oxidized low-density lipoproteins,190,191 remains to be explored. A seemingly distinct macrophage receptor belonging to the class B scavenger receptor I and CD36 has recently been described.192-194 Gene transfer of this receptor to nonphagocytic cells confers recognition for PS192 and apoptotic cells.193 This less-specific receptor also recognizes a variety of modified proteins, including oxidized LDL. Antibodies could also contribute to the removal of PS-expressing cells.13 For example, antiphospholipid syndrome antibodies that recognize plasma proteins bound to PS-expressing cells (or their microvesicles) can be expected to bind avidly to macrophages via the cells' Fc receptor. Other data indicate that members of the selectin family of adhesion molecules bind PS,126 suggesting that they can also function as PS receptors. In addition, β2-glycoprotein-I binds to intravenously injected PS-containing liposomes,195 suggesting that it could play a direct, antibody-independent role in the clearance of PS-expressing cells. It should be noted that PS-independent recognition mechanisms, including the vitronectin receptor (αVβ3 integrin) on bone marrow macrophages, are also involved in recognition and sequestration of apoptotic cells.14,196 The complexity of these recognition mechanisms is further illustrated by the observation that bone marrow macrophages can be stimulated to express the PS-binding characteristics of inflammatory macrophages.15 Lastly, it was recently reported that smooth muscle cells also recognize PS-expressing cells,8 suggesting that PS-dependent cell recognition is not limited to professional phagocytes.

The lipid transporter-controlled emergence of PS in the cell's outer leaflet results in the expression of altered surface properties that influence and regulate the cell's interaction with its environment. PS clearly plays a pivotal role in maintaining the delicate balance between hemostasis and thrombosis as its overexpression generates potentially dangerous thrombogenic surfaces. It is therefore essential that distinct, albeit cooperative mechanisms for the recognition and removal of PS-expressing cells exist. Understanding these mechanisms, as well as those that generate and regulate membrane lipid sidedness and those that promote a collapse of phospholipid asymmetry, is a starting point from which the role of lipid transporters in disease can be assessed.

The authors dedicate this article to the memory of Mrs Mary Ann Scott. We thank Drs E.M. Bevers, Y. Killion, and P. Comfurius for comments and critical review of the manuscript and are grateful to L. Feldman for her editorial assistance.

Supported in part by National Institutes of Health Grant No. DK41714.

Address reprint requests to Alan J. Schroit, PhD, Department of Cell Biology, Box 173, The University of Texas M.D. Anderson Cancer Center, 1500 Holcomble Blvd, Houston, TX 77030.

1
Seigneuret
M
Devaux
PF
Asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: Relation to shape changes.
Proc Natl Acad Sci USA
81
1984
3751
2
Bevers
EM
Comfurius
P
VanRijn
JLML
Hemker
HC
Zwaal
RFA
Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets.
Eur J Biochem
122
1982
429
3
Bevers
EM
Comfurius
P
Zwaal
RFA
Changes in membrane phospholipid distribution during platelet activation.
Biochim Biophys Acta
736
1983
57
4
Zwaal
RFA
Comfurius
P
VanDeenen
LLM
Membrane asymmetry and blood coagulation.
Nature
268
1977
358
5
Zwaal
RFA
Membrane and lipid involvement in blood coagulation.
Biochim Biophys Acta
515
1978
163
6
Fadok
VA
Voelker
DR
Campbell
PA
Cohen
JJ
Bratton
DL
Henson
PM
Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages.
J Immunol
148
1992
2207
7
Martin
SJ
Reutelingsperger
CPM
McGahon
AJ
Rader
JA
VanSchie
RCAA
Laface
DM
Green
DR
Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl.
J Exp Med
182
1995
1545
8
Bennett
MR
Gibson
DF
Schwartz
SM
Tait
JF
Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phosphatidylserine.
Circ Res
77
1995
1136
9
Casciola-Rosen
L
Rosen
A
Petri
M
Schlissel
M
Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: Implications for coagulation events and antigenic spread in systemic lupus erythematosis.
Proc Natl Acad Sci USA
93
1996
1624
10
Connor
J
Bucana
C
Fidler
IJ
Schroit
AJ
Differentiation-dependent expression of phosphatidylserine in mammalian plasma membranes: Quantitative assessment of outer leaflet lipid by prothrombinase complex formation PS asymmetry.
Proc Natl Acad Sci USA
86
1991
3184
11
Utsugi
T
Schroit
AJ
Connor
J
Bucana
CD
Fidler
IJ
Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes.
Cancer Res
51
1991
3062
12
Tanaka
Y
Schroit
AJ
Insertion of fluorescent phosphatidylserine into the plasma membrane of red blood cells: Recognition by autologous macrophages.
J Biol Chem
258
1983
11335
13
Schroit AJ, Madsen J, Tanaka Y:In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J Biol Chem 260:5131, 1985
14
Fadok
VA
Savill
JS
Haslett
C
Bratton
DL
Doherty
DE
Campbell
PA
Henson
PM
Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells.
J Immunol
149
1992
4029
15
Fadok
VA
Laszlo
D
Noble
PW
Weinstein
L
Riches
DWH
Henson
PM
Particle digestibility is required for induction of the phosphatidylserine recognition mechanism used by murine macrophages to phagocytose apoptotic cells.
J Immunol
151
1993
4274
16
Schroit
AJ
Zwaal
RFA
Transbilayer movement of phospholipids in red cell and platelet membranes.
Biochim Biophys Acta
1071
1991
313
17
Devaux
PF
Protein involvement in transmembrane lipid asymmetry.
Annu Rev Biophys Biomol Struct
21
1992
417
18
Devaux
PF
Zachowski
A
Maintenance and consequences of membrane phospholipid asymmetry.
Chem Phys Lipids
73
1994
107
19
Roelofsen B, OpdenKamp JAF: Plasma membrane phospholipid asymmetry and its maintenabce: The human erythrocyte as a model, in Hoekstra D (ed): Current Topics in Membranes, vol 40. New York, NY, Academic, 1994, p 7
20
Menon
AK
Flippases.
Trends Cell Biol
5
1995
355
21
Diaz
C
Schroit
AJ
Role of translocases in the generation of phosphatidylserine asymmetry.
J Membr Biol
151
1996
1
22
Daleke
DL
Huestis
WH
Incorporation and translocation of aminophospholipids in human erythrocytes.
Biochemistry
24
1985
5406
23
Connor
J
Schroit
AJ
Determination of lipid asymmetry in human red cells by resonance energy transfer.
Biochemistry
26
1987
5099
24
Morrot
G
Herve
P
Zachowski
A
Fellmann
P
Devaux
PF
Aminophospholipid translocase of human erythrocytes: Phospholipid substrate specificity and effect of cholesterol.
Biochemistry
28
1989
3456
25
Connor
J
Pak
CH
Zwaal
RFA
Schroit
AJ
Bidirectional transbilayer movement of phospholipid analogs in human red blood cells.
J Biol Chem
267
1992
19412
26
Beleznay
Z
Zachowski
A
Devaux
PF
Navazo
MP
Ott
P
ATP-dependent aminophospholipid translocation in erythrocyte vesicles — Stoichiometry of transport.
Biochemistry
32
1994
3146
27
Martin
OC
Pagano
RE
Transbilayer movement of fluorescent analogs of phosphatidylserine and phosphatidylethanolamine at the plasma membrane of cultured cells.
J Biol Chem
262
1987
5890
28
Connor
J
Schroit
AJ
Transbilayer movement of phosphatidylserine in erythrocytes. Inhibition of transport and preferential labeling of a 31,000 Dalton protein by sulfhydryl reactive reagents.
Biochemistry
27
1988
848
29
Connor
J
Schroit
AJ
Aminophospholipid translocation in erythrocytes: Evidence for the involvement of a specific transporter and an endofacial protein.
Biochemistry
29
1990
37
30
Bitbol
M
Fellmann
P
Zachowski
A
Devaux
PF
Ion regulation of phosphatidylserine and phosphatidylethanolamine outside-inside translocation in human erythrocytes.
Biochim Biophys Acta
904
1987
268
31
Tilly
RHJ
Senden
JMG
Comfurius
P
Bevers
EM
Zwaal
RFA
Increased aminophospholipid translocase activity in human platelets during secretion.
Biochim Biophys Acta
1029
1990
188
32
Morrot
G
Zachowski
A
Devaux
PF
Partial purification and ch a racterization of the human Mg2+-ATPase: A candidate aminophospholipid translocase.
FEBS Lett
266
1990
29
33
Zimmerman
ML
Daleke
DL
Regulation of a candidate aminophospholipid-transporting ATPase by lipid.
Biochemistry
32
1993
12257
34
Auland
ME
Morris
MB
Roufogalis
BD
Separation and characterization of two Mg(2+)-ATPase activities from the human erythrocyte membrane.
Arch Biochem Biophys
312
1994
272
35
Auland
ME
Roufogalis
BD
Devaux
PF
Zachowski
A
Reconstitution of ATP-dependent aminophospholipid translocation in proteoliposomes.
Proc Natl Acad Sci USA
91
1994
10938
36
Zachowski A, Dolis D, Moreau C, Devaux PF: Reconstitution of an aminophospholipid translocase activity in proteoliposomes. Conférence Jacques Monod (CNRS) 'Lipid diversity in membranes and cellular functions', La Londe les Maures, France. 1995, p 80 (abstr)
37
Schroit
AJ
Madsen
J
Ruoho
AE
Radioiodinated, photoaffinity-labeled phosphatidylcholine and phosphatidylserine. Transfer properties and differential photoreactive reaction with human erythrocyte membrane proteins.
Biochemistry
26
1987
1812
38
Connor
J
Schroit
AJ
Transbilayer movement of phosphatidylserine in non-human erythrocytes: Evidence that the aminophospholipid transporter is a ubiquitous membrane protein.
Biochemistry
28
1989
9680
39
Schroit
AJ
Bloy
C
Connor
J
Cartron
JP
Involvement of Rh blood group polypeptides in the maintenance of aminophospholipid asymmetry.
Biochemistry
29
1990
10303
40
Connor
J
Schroit
AJ
Transbilayer movement of phosphatidylserine in erythrocytes: Inhibitors of aminophospholipid transport block the association of photolabeled lipid to its transporter.
Biochim Biophys Acta
1066
1991
37
41
Higgins
CF
Flip-flop: The transmembrane translocation of lipids.
Cell
79
1994
393
42
Higgins
CF
P-glycoprotein. To flip or not to flip?
Curr Biol
4
1994
259
43
Zachowski
A
Henry
JP
Devaux
PF
Control of transmembrane lipid asymmetry in chromaffin granules by an ATP-dependent protein.
Nature
340
1989
75
44
Herrmann
A
Zachowski
A
Devaux
PF
Protein-mediated phospholipid translocation in the endoplasmatic reticulum with a low lipid specificity.
Biochemistry
29
1990
2023
45
Sune
A
Bette-Bobillo
P
Bienvenue
A
Fellmann
P
Devaux
PF
Selective outside-inside translocation of aminophospholipids in human platelets.
Biochemistry
26
1987
2972
46
Smeets
EF
Comfurius
P
Bevers
EM
Zwaal
RFA
Calcium-induced transbilayer scrambling of fluorescent phospholipid analogs in platelets and erythrocytes.
Biochim Biophys Acta
1195
1994
281
47
Zachowski
A
Gaudry-Talarmain
YM
Phospholipid transverse diffusion in synaptosomes: Evidence for the involvement of the aminophospholipid translocase.
J Neurochem
55
1990
1352
48
Muller
K
Labbe
C
Zachowski
A
Phospholipid transverse asymmetry in trout spermatozoa plasma membrane.
Biochim Biophys Acta
1192
1994
21
49
Muller
K
Pomorski
T
Muller
P
Zachowski
A
Herrmann
A
Protein-dependent translocation of aminophospholipids and asymmetric transbilayer distribution of phospholipids in the plasma membrane of ram sperm cells.
Biochemistry
33
1994
9968
50
Pomorski
T
Müller
P
Zimmermann
B
Burger
K
Devaux
PF
Herrmann
A
Transbilayer movementof fluorescent and spin-labeled phospholipids in the plasma membrane of human fibroblasts: A quantitative approach.
J Cell Sci
109
1996
687
51
Julien
M
Tournier
JF
Tocanne
JF
Basic fibroblast growth factor modulates the aminophospholipid translocase activity present in the plasma membrane of bovine aortic endothelial cells.
Eur J Biochem
230
1995
287
52
Hanada
K
Pagano
RE
A Chinese hamster ovary cell mutant defective in the non-endocytic uptake of fluorescent analogs of phosphatidylserine: Isolation using a cytosol acidification protocol.
J Cell Biol
128
1995
793
53
Bitbol
M
Devaux
PF
Measurement of outward translocation of phospholipids across human erythrocyte membrane.
Proc Nat Acad Sci USA
85
1988
6783
54
Connor
J
Gillum
K
Schroit
AJ
Maintenance of lipid asymmetry in red blood cells and ghosts. Effect of divalent cations and serum albumin on the transbilayer distribution of phosphatidylserine.
Biochim Biophys Acta
1025
1990
82
55
Andrick
C
Broring
K
Deuticke
B
Haest
CWM
Fast translocation of phosphatidylcholine to the outer membrane leaflet after its synthesis at the inner membrane surface in human erythrocytes.
Biochim Biophys Acta
1064
1991
235
56
Sugihara
T
Sugihara
K
Hebbel
RP
Phospholipid asymmetry during erythrocyte deformation: Maintenance of the unit membrane.
Biochim Biophys Acta
1103
1992
303
57
Comfurius
P
Senden
JM
Tilly
RH
Schroit
AJ
Bevers
EM
Zwaal
RFA
Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocase.
Biochim Biophys Acta
1026
1990
153
58
Devaux
PF
Static and dynamic lipid asymmetry in cell membranes.
Biochemistry
30
1991
1163
59
Lucy
JA
Loss of phospholipid asymmetry in cell fusion.
Biochem Soc Trans
21
1993
280
60
Farge
E
Increased vesicle endocytosis due to an increase in the plasma membrane phosphatidylserine concentration.
Biophys J
69
1995
2501
61
Zwaal
RFA
Comfurius
P
Bevers
EM
Mechanism and function of changes in membrane-phospholipid asymmetry in platelets and erythrocytes.
Biochem Soc Trans
21
1993
248
62
Rosing
J
Bevers
EM
Comfurius
P
Hemker
HC
VanDieijen
G
Weiss
HJ
Zwaal
RFA
Impaired factor X and prothrombin activation associated with decreased phospholipid exposure in platelets from a patient with a bleeding disorder.
Blood
65
1985
1557
63
Weiss
HJ
Scott syndrome: A disorder of platelet coagulant activity.
Semin Hematol
31
1994
312
64
Toti
F
Satta
N
Fressinaud
E
Meyer
D
Freyssinet
JM
Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder.
Blood
87
1996
1409
65
Williamson
P
Bevers
EM
Smeets
EF
Comfurius
P
Schlegel
RA
Zwaal
RFA
Continuous analysis of the mechanism of activated transbilayer lipid movement in platelets.
Biochemistry
34
1995
10448
66
Williamson
P
Kulick
A
Zachowski
A
Schlegel
RA
Devaux
PF
Ca2+ induces transbilayer redistribution of all major phospholipids in human erythrocytes.
Biochemistry
31
1992
6355
67
Sulpice
JC
Zachowski
A
Devaux
PF
Giraud
F
Requirement for phosphatidylinos itol 4,5-bisphosphate in the Ca2+-induced phospholipid redistribution in the human erythrocyte membrane.
J Biol Chem
269
1994
6347
68
Martin
DW
Jesty
J
Calcium stimulation of procoagulant activity in human erythrocytes. ATP dependence and the effects of modifiers of stimulation and recovery.
J Biol Chem
270
1995
10468
69
Comfurius
P
Williamson
P
Smeets
EF
Schlegel
RA
Bevers
EM
Zwaal
RFA
Reconstitution of phospholipid scramblase activity from human blood platelets.
Biochemistry
35
1996
7631
70
Bassé
F
Stout
JG
Sims
PJ
Wiedmer
T
Isolation of an erythrocyte membrane protein that mediates Ca2+-dependent transbilayer movement of phospholipid.
J Biol Chem
271
1996
17205
71
Bevers
EM
Wiedmer
T
Comfurius
P
Zhao
J
Smeets
EF
Schlegel
RA
Schroit
AJ
Weiss
HJ
Williamson
P
Zwaal
RFA
Sims
PJ
The complex of phosphatidylinositol 4,5-bisphosphate and calcium ions is not responsible for Ca2+-induced loss of phospholipid asymmetry in the human erythrocyte: A study in Scott syndrome, a disorder of calcium-induced phospholipid scrambling.
Blood
86
1995
1983
72
Sims
PJ
Wiedmer
T
Esmon
CT
Weiss
HJ
Shattil
SJ
Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: An isolated defect in platelet procoagulant activity.
J Biol Chem
264
1989
17049
73
Wiedmer
T
Shattil
SJ
Cunningham
M
Sims
PJ
Role of calcium and calpain in complement-induced vesiculation of the platelet plasma membrane and in the exposure of the platelet factor Va receptor.
Biochemistry
29
1990
623
74
Zwaal
RFA
Comfurius
P
Bevers
EM
Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis.
Biochim Biophys Acta
1180
1992
1
75
Dachary-Prigent
J
Freyssinet
JM
Pasquet
JM
Carron
JC
Nurden
AT
Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: A flow cytometry study showing a role for free sulfhydryl groups.
Blood
81
1993
2554
76
Fox
JEB
Austin
CD
Reynolds
C
Steffen
PK
Evidence that agonist-induced activation of calpain causes the shedding of procoagulant-containing microvesicles from the membrane of aggregating platelets.
J Biol Chem
266
1991
13289
77
Dachary-Prigent
J
Pasquet
JM
Freyssinet
JM
Nurden
AT
Calcium involvement in aminophospholipid exposure and microparticle formation during platelet activation: A study using Ca2+-ATPase inhibitors.
Biochemistry
34
1995
11625
78
Geldwerth
D
Kuypers
FA
Butikofer
P
Allary
M
Lubin
BH
Devaux
PF
Transbilayer mobility and distribution of red cell phospholipids during storage.
J Clin Invest
93
1993
92
79
Tait
JF
Gibson
D
Measurement of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding.
J Lab Clin Med
123
1994
741
80
Sestier
C
Sabolovic
D
Geldwerth
D
Moumaris
M
Roger
J
Pons
JN
Halbreich
A
Use of annexin V-ferrofluid to enumerate erythrocytes damaged in various pathologies or during storage in vitro.
CR Acad Sci III
318
1995
1141
81
Chiu
D
Lubin
B
Shohet
SB
Erythrocyte membrane lipid reorganization during the sickling process.
Br J Haematol
41
1979
223
82
Chiu
D
Lubin
B
Roelofsen
B
VanDeenen
LLM
Sickled erythrocytes accelerate clotting in vitro: An effect of abnormal membrane lipid asymmetry.
Blood
58
1981
398
83
Kuypers
FA
Lewis
RA
Hua
M
Schott
MA
Discher
D
Ernst
JD
Lubin
BH
Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently-labeled annexin V.
Blood
87
1996
1179
84
Liu
SC
Yi
SJ
Mehta
JR
Nichols
PE
Ballas
SK
Yacono
PW
Golan
DE
Palek
J
Red cell membrane remodeling in sickle cell anemia. Sequestration of membrane lipids and proteins in Heinz bodies.
J Clin Invest
97
1996
29
85
Wali
RK
Jaffe
S
Kumar
D
Kalra
VK
Alterations in organization of phospholipids in erythrocytes as factor in adherence to endothelial cells in diabetes mellitus.
Diabetes
37
1988
104
86
Wilson
MJ
Richterlowney
K
Daleke
DL
Hyperglycemia induces a loss of phospholipid asymmetry in human erythrocytes.
Biochemistry
32
1993
11302
87
Connor
J
Pak
CC
Schroit
AJ
Exposure of phosphatidylserine in the outer leaflet of human red blood cells: Relationship to cell density, cell age, and clearance by mononuclear cells.
J Biol Chem
269
1994
2399
88
Diaz
C
Morkowski
J
Schroit
AJ
Generation of phenotypically aged phosphatidylserine-expressing erythrocytes by dilauroylphosphatidylcholine-induced vesiculation.
Blood
87
1996
2956
89
Haest
CWM
Plasa
G
Kamp
D
Deuticke
B
Spectrin as a stabilizer of the phospholipid asymmetry in the human erythrocyte membrane.
Biochim Biophys Acta
509
1978
21
90
Haest
CWM
Interactions between membrane skeleton proteins and the intrinsic domain of the erythrocyte membrane.
Biochim Biophys Acta
694
1982
331
91
Franck
PFH
Bevers
EM
Lubin
BH
Comfurius
P
Chiu
DT-Y
OpDenKamp
JAF
Zwaal
RFA
VanDeenen
LLM
Roelofsen
B
Uncoupling of the membrane skeleton from the lipid bilayer: The cause of accelerated phospholipid flip-flop leading to enhanced procoagulant activity of sickled cells.
J Clin Invest
75
1985
183
92
Calvez
J-Y
Zachowski
A
Herrmann
A
Morrot
G
Devaux
PF
Asymmetric distribution of phospholipids in spectrin-poor erythrocyte vesicles.
Biochemistry
27
1988
5666
93
Bruckheimer
EB
Gillum
KD
Schroit
AJ
Co-localization of Rh polypeptides and the aminophospholipid transporter in dilauroylphosphatidylcholine-induced erythrocyte vesicles.
Biochim Biophys Acta
1235
1995
147
94
Kuypers
FA
Lubin
BH
Yee
M
Agre
P
Devaux
PF
Geldwerth
D
The distribution of erythrocyte phospholipids in hereditary spherocytosis demonstrates a minimal role for erythrocyte spectrin on phospholipid diffusion and asymmetry.
Blood
81
1993
1051
95
Smit
JJM
Schinkel
AH
Oude
Elferink RPJ
Groen
AK
Wagenaar
E
VanDeemter
L
Mol
CAAM
Ottenhoff
R
VanDerLugt
NM
VanRoon
MA
VanDerValk
MA
Offerhaus
GJA
Berns
AJM
Borst
P
Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease.
Cell
75
1993
451
96
Oude
Elferink RPJ
Groen
AK
The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology.
J Hepatol
23
1995
617
97
Higgins
CF
Gottesman
MM
Is the multidrug transporter a flippase?
Trends Biochem Sci
17
1992
18
98
Homolya
L
Hollo
Z
Germann
UA
Pastan
I
Gottesman
MM
Sarkadi
B
Fluorescent cellular indicators are extruded by the multidrug resistance protein.
J Biol Chem
268
1993
21493
99
Basse
F
Gaffet
P
Rendu
F
Bienvenue
A
Translocation of spin-labeled phospholipids through plasma membrane during thrombin-induced and ionophore-A23187-induced platelet activation.
Biochemistry
32
1993
2337
100
Gaffet
P
Bettache
N
Bienvenue
A
Transverse redistribution of phospholipids during human platelet activation: Evidence for a vectorial outflux specific to aminophospholipids.
Biochemistry
34
1995
6762
101
Chang
CP
Zhao
J
Wiedmer
T
Sims
PJ
Contribution of platelet microparticle formation and granule secretion to the transmembrane migration of phosphatidylserine.
J Biol Chem
268
1993
7171
102
Bevers
EM
Wiedmer
T
Comfurius
P
Shattil
SJ
Weiss
HJ
Zwaal
RFA
Sims
PJ
Defective Ca2+-induced microvesiculation and deficient expression of procoagulant activity in erythrocytes from a patient with a bleeding disorder: A study of the red blood cells of Scott syndrome.
Blood
79
1992
380
103
Farge
E
Devaux
PF
Shape changes of giant liposomes induced by an asymmetric transmembrane distribution of phospholipids.
Biophys J
61
1992
347
104
Nemerson
Y
The tissue factor pathway of blood coagulation.
Semin Hematol
29
1992
170
105
Esmon
CT
Cell mediated events that control blood coagulation and vascular injury.
Annu Rev Cell Biol
9
1993
1
106
Kalafatis
M
Swords
NA
Rand
MD
Mann
KG
Membrane-dependent reactions in blood coagulation: Role of the vitamin K-dependent enzyme complexes.
Biochim Biophys Acta
1227
1994
113
107
Andree
HAM
Nemerson
Y
Tissue factor: Regulation of activity by flow and phospholipid surfaces.
Blood Coagul Fibrinol
6
1995
189
108
Bach
R
Gentry
R
Nemerson
Y
Factor VII binding to tissue factor in reconstituted phospholipid vesicles: Induction of cooperativity by phosphatidylserine.
Biochemistry
25
1986
4007
109
Bach
R
Rifkin
DB
Expression of tissue factor procoagulant activity: Regulation by cytosolic calcium.
Proc Natl Acad Sci USA
87
1990
6995
110
Ruf
W
Rehemtulla
A
Morrissey
JH
Edgington
TS
Phospholipid-independent and dependent interactions required for tissue factor receptor and cofactor function.
J Biol Chem
266
1991
2158
111
Mann
KG
Nesheim
ME
Church
WR
Haley
P
Krishnaswamy
S
Surface-dependent reactions of the vitamin K-dependent enzyme complexes.
Blood
76
1990
1
112
Rosing
J
Speijer
H
Zwaal
RFA
Prothrombin activation on phospholipid membranes with positive electrostatic potential.
Biochemistry
27
1988
8
113
Gilbert
GE
Drinkwater
D
Specific membrane binding of factor VIII is mediated by O-phospho-L-serine, a moiety of phosphatidylserine.
Biochemistry
32
1993
9577
114
Comfurius
P
Smeets
EF
Willems
GM
Bevers
EM
Zwaal
RFA
Assembly of the prothrombinase complex on lipid vesicles depends on the stereochemical configuration of the polar headgroup of phosphatidylserine.
Biochemistry
33
1994
10319
115
Tans
G
Rosing
J
Thomassen
MCLGD
Heeb
MJ
Zwaal
RFA
Griffin
JH
Comparison of anticoagulant and procoagulant properties of stimulated platelets and platelet-derived microparticles.
Blood
77
1991
2641
116
Bevers
EM
Comfurius
P
Zwaal
RFA
The nature of the binding site for prothrombinase at the platelet surface as revealed by lipolytic enzymes.
Eur J Biochem
122
1982
81
117
Thiagarajan
P
Tait
JF
Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets.
J Biol Chem
265
1990
17420
118
Rao
LV
Tait
JF
Hoang
AD
Binding of annexin V to a human ovarian carcinoma cell line (OC-2008). Contrasting effects on cell surface factor VIIa/tissue factor activity and prothrombinase activity.
Thromb Res
67
1992
517
119
Rosing
J
VanRijn
JLML
Bevers
EM
VanDieijen
G
Comfurius
P
Zwaal
RFA
The role of activated human platelets in prothrombin and factor X activation.
Blood
65
1985
319
120
Zwaal
RFA
Bevers
EM
Comfurius
P
Rosing
J
Tilly
RHJ
Verhallen
PFJ
Loss of membrane phospholipid asymmetry during activation of blood platelets and sickled red cells: Mechanism and physiological significance.
Mol Cell Biochem
91
1989
23
121
Sims
PJ
Faioni
EM
Wiedmer
T
Shattil
SJ
Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity.
J Biol Chem
263
1988
18205
122
Holme
PA
Solum
NO
Brosstad
F
Roger
M
Abdelnoor
M
Demonstration of platelet-derived microvesicles in blood from patients with activated coagulation and fibrinolysis using a filtration technique and Western blotting.
Thromb Haemost
72
1994
666
123
Lee
Y
Jy
W
Horstman
LL
Janania J
Kelley
R
Ahn
YS
Elevated platelet microparticles in multiinfarct dementias and transient ischemic attacks.
Thromb Res
72
1993
295
124
Jy
W
Horstman
LL
Wang
F
Duncan
R
Ahn
YS
Platelet factor 3 in plasma fractions: Its relation to microparticle size and thromboses.
Thromb Res
80
1995
471
125
Jy
W
Mao
WW
Horstman
LL
Tao
J
Ahn
YS
Platelet microparticles bind, activate and aggregate neutrophils in vitro.
Blood Cells Mol Dis
21
1995
217
126
Malhotra
R
Taylor
NR
Bird
MI
Anionic phospholipids bind to L-selectin (but not E-selectin) at a site distinct from the carbohydrate-binding site.
Biochem J
314
1996
297
127
Bona
R
Lee
E
Rickles
F
Tissue factor apoprotein: Intracellular transport and expression in shed membrane vesicles.
Thromb Res
48
1987
487
128
Dvorak
HF
Van DeWater
L
Bitzer
AM
Dvorak
AM
Anderson
D
Harvey
VS
Bach
R
Davis
GL
DeWolf
W
Carvalho
AC
Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells.
Cancer Res
43
1983
4434
129
Weiss
HJ
Vivic
WJ
Lages
BA
Rogers
J
Isolated deficiency of platelet procoagulant activity.
Am J Med
67
1979
206
130
Miletich
JP
Kane
WH
Hofmann
SL
Stanford
N
Majerus
PW
Deficiency of factor Xa-factor Va binding sites on the platelets of a patient with a bleeding disorder.
Blood
54
1979
1015
131
Ahmad
SS
Rawala-Sheikh
R
Ashby
B
Walsh
PN
Platelet receptor-mediated factor X activation by factor IXa. High-affinity factor IXa receptors induced by factor VIII are deficient on platelets in Scott Syndrome.
J Clin Invest
84
1989
824
132
Kojima
H
Newton-Nash
D
Weiss
HJ
Zhao
J
Sims
PJ
Wiedmer
T
Production and characterization of transformed B-lymphocytes expressing the membrane defect of Scott syndrome.
J Clin Invest
94
1994
2237
133
Chandra
R
Joshi
PC
Bajpaj
VK
Gupta
CM
Membrane phospholipid organization in calcium-loaded human erythrocytes.
Biochim Biophys Acta
902
1987
253
134
Lupu
C
Calb
M
Ionescu
M
Lupu
F
Enhanced prothrombin and intrinsic factor X activation on blood platelets from diabetic patients.
Thromb Haemost
70
1993
579
135
Epand
RM
Stafford
A
Leon
B
Lock
PE
Tytler
EM
Segrest
JP
Anantharamaiah
GM
HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity.
Arterioscler Thromb
14
1994
1775
136
Tracy
PB
Eide
LL
Mann
KG
Human prothrombinase complex assembly and function on isolated peripheral blood cell populations.
J Biol Chem
260
1985
2119
137
Tracy
PB
Regulation of thrombin generation at cell surfaces.
Semin Thromb Haemost
14
1988
227
138
Robinson
RA
Worfolk
L
Tracy
PB
Endotoxin enhances the expression of monocyte prothrombinase activity.
Blood
79
1992
406
139
Satta
N
Toti
F
Feugeas
O
Bohbot
A
Dachary-Prigent
J
Eschwège
V
Hedman
H
Freyssinet
JM
Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharides.
J Immunol
153
1994
3245
140
Gregory
SA
Morrissey
JH
Edgington
TS
Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin.
Mol Cell Biol
9
1989
2752
141
Rapaport
SI
Rao
LVM
Initiation and regulation of tissue factor-dependent blood coagulation.
Arterioscler Thromb
12
1992
1111
142
Hamilton
KK
Hattori
R
Esmon
CT
Sims
PJ
Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex.
J Biol Chem
265
1990
3809
143
VanDeMeer
BW
Fugate
RD
Sims
PJ
Complement proteins C5b-9 induce transbilayer migration of membrane phospholipids.
Biophys J
56
1989
935
144
Fattal
E
Nir
S
Parente
RA
Szoka
FC
Pore-forming peptides induce rapid phospholipid flip-flop in membranes.
Biochemistry
33
1994
6721
145
Almers
W
Exocytosis.
Annu Rev Physiol
52
1990
607
146
Andoh
K
Kubota
T
Takada
M
Tanaka
H
Kobayashi
N
Maekawa
T
Tissue factor activity in leukemia cells. Special reference to disseminated intravascular coagulation.
Cancer
59
1987
748
147
Bauer
KA
Conway
EM
Bach
R
Konigsberg
WH
Griffin
JD
Demetri
G
Tissue factor gene expression in acute myeloblastic leukemia.
Thromb Res
56
1989
425
148
Tallman
MS
Kwaan
HC
Reassessing the hemostatic disorder associated with acute promyelocytic leukemia.
Blood
79
1992
543
149
Falanga
A
Gordon
SG
Isolation and characterization of cancer procoagulant: A cysteine proteinase from malignant tissue.
Biochemistry
24
1985
5558
150
Donati
MB
Gambacorti-Passerini
C
Casali
B
Falanga
A
Vannotti
P
Fossati
G
Semeraro
N
Gordon
SG
Cancer procoagulant in human tumor cells: Evidence from melanoma patients.
Cancer Res
46
1986
6471
151
Falanga
A
Iacoviello
L
Evangelista
V
Belotti
D
Consonni
R
D'Orazio
A
Robba
L
Donati
MB
Barbui
T
Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid.
Blood
86
1995
1072
152
VanDeWater
L
Tracy
PB
Aronson
D
Mann
KG
Dvorak
HF
Tumor cell generation of thrombin via functional prothrombinase assembly.
Cancer Res
45
1985
5521
153
Sugimura
M
Donato
R
Kakkar
VV
Scully
MF
Annexin V as a probe of the contribution of anionic phospholipids to the procoagulant activity of tumor cell surfaces.
Blood Coagul Fibrinol
5
1994
365
154
Bastida
E
Ordinas
A
Escolar
G
Jamieson
GA
Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis.
Blood
64
1984
177
155
McNeil
HP
Chesterman
CN
Krilis
SA
Immunology and clinical importance of antiphospholipid antibodies.
Adv Immunol
49
1991
193
156
Roubey
RA
Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other “antiphospholipid” autoantibodies.
Blood
84
1994
2854
157
McNeil
HP
Simpson
RJ
Chesterman
CN
Krilis
SA
Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H).
Proc Natl Acad Sci USA
87
1990
4120
158
Galli
M
Comfurius
P
Maassen
C
Hemker
HC
DeBaets
MH
VanBreda-Vriesman
PJC
Barbui
T
Zwaal
RFA
Bevers
EM
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.
Lancet
335
1990
1544
159
Bevers
EM
Galli
M
Barbui
T
Comfurius
P
Zwaal
RFA
Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin.
Thromb Haemost
66
1991
629
160
Oosting
JD
Derksen
RH
Bobbink
IW
Hackeng
TM
Bouma
BN
DeGroot
PG
Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism?
Blood
81
1993
2618
161
Permpikul
P
Rao
LV
Rapaport
SI
Functional and binding studies of the roles of prothrombin and β2-glycoprotein I in the expression of lupus anticoagulant activity.
Blood
83
1994
2878
162
Pengo
V
Biasiolo
A
Brocco
T
Tonetto
S
Ruffatti
A
Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies.
Thromb Haemost
75
1996
721
163
Galli
M
Bevers
EM
Comfurius
P
Barbui
T
Zwaal
RFA
Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles.
Br J Haematol
83
1993
466
164
Ciaudo
M
Horellou
MH
Audouin
J
De Carbonnieres
C
Conard
J
Samama
M
Lupus anticoagulant associated with primary malignant lymphoplasmacytic lymphoma of the spleen: A report of four patients.
Am J Hematol
38
1991
271
165
Fidler
IJ
Schroit
AJ
Recognition and destruction of neoplastic cells by activated macrophages. Discrimination of altered self.
Biochim Biophys Acta
948
1988
151
166
Pak
CC
Fidler
IJ
Molecular mechanisms for activated macrophage recognition of tumor cells.
Semin Cancer Biol
2
1991
189
167
Poste
G
Bucana
C
Raz
A
Bugelski
P
Kirsh
R
Fidler
IJ
Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery.
Cancer Res
42
1982
1412
168
Raz
A
Bucana
C
Fogler
WE
Poste
G
Fidler
IJ
Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages.
Cancer Res
41
1981
487
169
Schroit
AJ
Fidler
IJ
Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by muramyl dipeptide liposomes.
Cancer Res
42
1982
161
170
Lane
A
O'Connell
JL
Marlar
RA
Erythrocyte membrane vesicles and irreversibly sickled cells bind protein.
Am J Hematol
47
1994
295
171
Borenstain-Ben
Yashar V
Barenholz
Y
Hy-Am
E
Rachmilewitz
EA
Eldor
A
Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes.
Am J Hematol
44
1993
63
172
Blumenfeld
N
Zachowski
A
Galacteros
F
Beuzard
Y
Devaux
PF
Transmembrane mobility of phospholipids in sickle erythrocytes: Effect of deoxygenation on diffusion and asymmetry.
Blood
77
1991
849
173
Muller
P
Zachowski
A
Beuzard
Y
Devaux
PF
Transmembrane mobility and distribution of phospholipids in the membrane of mouse beta-thalassaemic red blood cells.
Biochim Biophys Acta
1151
1993
7
174
Schwartz
RS
Tanaka
Y
Fidler
IJ
Chiu
D
Lubin
B
Schroit
AJ
Increased adherence of sickled and phosphatidylserine enriched human erythrocytes to cultured human peripheral blood monocytes.
J Clin Invest
75
1985
1965
175
Pak
CC
Fidler
IJ
Activated macrophages distinguish undifferentiated-tumorigenic from differentiated-nontumorigenic murine erythroleukemia cells.
Differentiation
41
1989
49
176
Bartosz
G
Erythrocyte aging: Physical and chemical membrane changes.
Gerontology
37
1991
33
177
Piomelli
S
Seaman
C
Mechanism of red blood cell aging: Relationship of cell density and cell age.
Am J Hematol
42
1993
46
178
Herrmann
A
Devaux
PF
Alteration of the aminophospholipid translocase activity during in vivo and artificial aging of human erythrocytes.
Biochim Biophys Acta
1027
1990
41
179
Gaffet
P
Basse
F
Bienvenue
A
Loss of phospholipid asymmetry in human platelet plasma membrane after 1-12 days of storage. An ESR study.
Eur J Biochem
222
1994
1033
180
Jain
SK
The accumulation of malonyldialdehyde, a product of fatty acid peroxidation, can disturb aminophospholipid organization in the membrane bilayer of human erythrocytes.
J Biol Chem
259
1984
3391
181
Jain
SK
In vivo externalization of phosphatidylserine and phosphatidylethanolamine in the membrane bilayer and hypercoagulability by the lipid peroxidation of erythrocytes in rats.
J Clin Invest
76
1985
281
182
Bevers
EM
Tilly
RH
Senden
JM
Comfurius
P
Zwaal
RFA
Exposure of endogenous phosphatidylserine at the outer surface of stimulated platelets is reversed by restoration of aminophospholipid translocase activity.
Biochemistry
28
1989
2382
183
Jain
SK
Evidence for membrane lipid peroxidation during the in vivo aging of human erythrocytes.
Biochim Biophys Acta
937
1988
205
184
Koopman
G
Reutelingsperger
CPM
Kuijten
GAM
Keehnen
RMJ
Pals
ST
VanOers
MHJ
Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis.
Blood
84
1994
1415
185
Verhoven
B
Schlegel
RA
Williamson
P
Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal on apoptotic T lymphocytes.
J Exp Med
182
1995
1597
186
Mower
DA
Peckham
DW
Illera
VA
Fishbaugh
JK
Stunz
LL
Ashman
RF
Decreased membrane phospholipid packing and decreased cell size precede DNA cleavage in mature mouse B cell apoptosis.
J Immunol
152
1994
4832
187
Ashman
RF
Peckham
D
Alhasan
S
Stunz
LL
Membrane unpacking and rapid disposal of apoptotic cells.
Immunol Lett
48
1995
159
188
Squier
MK
Miller
AC
Malkinson
AM
Cohen
JJ
Calpain activation in apoptosis.
J Cell Physiol
159
1994
229
189
Ramprasad
MP
Fischer
W
Witztum
JL
Sambrano
GR
Quehenberger
O
Steinberg
D
The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68.
Proc Natl Acad Sci USA
92
1995
9580
190
Ottnad
E
Parthasarathy
S
Sambrano
GR
Ramprasad
MP
Quehenberger
O
Kondratenko
N
Green
S
Steinberg
D
A macrophage receptor for oxidized low density lipoprotein distinct from the receptor for acetyl low density lipoprotein: Partial purification and role in recognition of oxidatively damaged cells.
Proc Natl Acad Sci USA
92
1995
1391
191
Sambrano
GR
Steinberg
D
Recognition of oxidatively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: Role of membrane phosphatidylserine.
Proc Natl Acad Sci USA
92
1995
1396
192
Rigotti
A
Acton
SL
Krieger
M
The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids.
J Biol Chem
270
1995
16221
193
Ren
Y
Silverstein
RL
Allen
J
Savill
J
CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis.
J Exp Med
181
1995
1857
194
Fukasawa
M
Adachi
H
Hirota
K
Tsujimoto
M
Arai
H
Inoue
K
SRB1, a class B scavenger receptor, recognizes both negatively charged liposomes and apoptotic cells.
Exp Cell Res
222
1996
246
195
Chonn
A
Semple
SC
Cullis
PR
Beta 2 glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of “non-self” particles.
J Biol Chem
270
1995
25845
196
Savill
J
Fadok
V
Henson
P
Haslett
C
Phagocyte recognition of cells undergoing apoptosis.
Immunol Today
14
1993
131
Sign in via your Institution